id	sid	eid	entity	type
dpc-4503	2	1	2024;14(4):e2024250	CARDINAL
dpc-4503	2	2	1	CARDINAL
dpc-4503	2	3	luigi gargiulo1,2	PERSON
dpc-4503	2	4	luciano ibba1,2	PERSON
dpc-4503	2	5	alessandra narcisi1	PERSON
dpc-4503	2	6	silvia giordano3	PERSON
dpc-4503	2	7	carlo a. maronese4,5	PERSON
dpc-4503	2	8	fabrizio martora6	PERSON
dpc-4503	2	9	federica repetto3	PERSON
dpc-4503	2	10	giovanni paolino7	PERSON
dpc-4503	2	11	anna balato8	PERSON
dpc-4503	2	12	martina burlando9	PERSON
dpc-4503	2	13	paolo dapavo3	PERSON
dpc-4503	2	14	valentina dini10	PERSON
dpc-4503	2	15	claudio guarneri11	PERSON
dpc-4503	2	16	angelo v. marzano4,5	PERSON
dpc-4503	2	17	matteo megna6	PERSON
dpc-4503	2	18	santo r. mercuri7	PERSON
dpc-4503	2	19	antonio costanzo1,2	PERSON
dpc-4503	2	20	mario valenti1,2 1	PERSON
dpc-4503	2	21	humanitas research hospital	ORG
dpc-4503	2	22	milan	GPE
dpc-4503	2	23	italy 2	ORG
dpc-4503	2	24	biomedical sciences	ORG
dpc-4503	2	25	humanitas university	ORG
dpc-4503	2	26	pieve emanuele	PERSON
dpc-4503	2	27	milan	GPE
dpc-4503	2	28	italy 3	ORG
dpc-4503	2	29	second	ORDINAL
dpc-4503	2	30	university of turin	ORG
dpc-4503	2	31	turin	GPE
dpc-4503	2	32	italy 4	GPE
dpc-4503	2	33	fondazione irccs	ORG
dpc-4503	2	34	granda ospedale maggiore policlinico	PERSON
dpc-4503	2	35	milan	GPE
dpc-4503	2	36	italy 5	ORG
dpc-4503	2	37	università degli studi di milano	ORG
dpc-4503	2	38	milan	GPE
dpc-4503	2	39	italy 6	ORG
dpc-4503	2	40	university of naples federico ii	ORG
dpc-4503	2	41	naples	GPE
dpc-4503	2	42	italy 7	ORG
dpc-4503	2	43	ospedale san raffaele	ORG
dpc-4503	2	44	milan	GPE
dpc-4503	2	45	italy	GPE
dpc-4503	3	1	milan	GPE
dpc-4503	3	2	italy 8	ORG
dpc-4503	3	3	university of campania l. vanvitelli	ORG
dpc-4503	3	4	naples	GPE
dpc-4503	3	5	italy 9	ORG
dpc-4503	3	6	di scienze della	ORG
dpc-4503	3	7	university of genoa	ORG
dpc-4503	3	8	ospedale policlinico	ORG
dpc-4503	3	9	san martino	GPE
dpc-4503	3	10	genoa	GPE
dpc-4503	3	11	italy	GPE
dpc-4503	3	12	10	CARDINAL
dpc-4503	3	13	santa chiara	GPE
dpc-4503	3	14	pisa, italy 11	ORG
dpc-4503	3	15	university of messina	ORG
dpc-4503	3	16	aou policlinico g. martino	PERSON
dpc-4503	3	17	messina	GPE
dpc-4503	3	18	italy	GPE
dpc-4503	3	19	hs	PERSON
dpc-4503	6	1	2024;14(4):e2024250	CARDINAL
dpc-4503	7	1	june 24, 2024	DATE
dpc-4503	8	1	october 2024	DATE
dpc-4503	8	2	2024	CARDINAL
dpc-4503	9	1	https://creativecommons.org/licenses/by-nc/4.0/	ORG
dpc-4503	11	1	l. gargiulo	PERSON
dpc-4503	11	2	ucb pharma	GPE
dpc-4503	12	1	l. ibba	PERSON
dpc-4503	13	1	a. narcisi	PERSON
dpc-4503	13	2	leo pharma	PERSON
dpc-4503	13	3	janssen	GPE
dpc-4503	13	4	novartis	LOC
dpc-4503	13	5	amgen	ORG
dpc-4503	13	6	boehringer ingelheim	ORG
dpc-4503	14	1	a. balato	PERSON
dpc-4503	14	2	eli lilly	ORG
dpc-4503	14	3	novartis pharma	ORG
dpc-4503	14	4	sanofi-genzyme	ORG
dpc-4503	14	5	ucb pharma	PERSON
dpc-4503	15	1	m. burlando	PERSON
dpc-4503	15	2	janssen	GPE
dpc-4503	15	3	amgen	ORG
dpc-4503	15	4	novartis	ORG
dpc-4503	15	5	lilly	ORG
dpc-4503	15	6	ucb pharma	ORG
dpc-4503	16	1	novartis	ORG
dpc-4503	16	2	sanofi	ORG
dpc-4503	16	3	ucb	GPE
dpc-4503	16	4	janssen	GPE
dpc-4503	16	5	lilly	ORG
dpc-4503	17	1	c. guarneri	PERSON
dpc-4503	17	2	janssen	GPE
dpc-4503	17	3	eli lilly	ORG
dpc-4503	17	4	novartis	ORG
dpc-4503	17	5	sanofi	ORG
dpc-4503	17	6	leo pharma	PERSON
dpc-4503	18	1	a. v. marzano	PERSON
dpc-4503	18	2	boehringer-ingelheim	ORG
dpc-4503	18	3	novartis	ORG
dpc-4503	18	4	sanofi	ORG
dpc-4503	18	5	ucb	GPE
dpc-4503	18	6	m. megna	PERSON
dpc-4503	18	7	eli lilly	ORG
dpc-4503	18	8	janssen	GPE
dpc-4503	18	9	leo-pharma	PERSON
dpc-4503	18	10	ucb	GPE
dpc-4503	18	11	novartis	ORG
dpc-4503	19	1	a. costanzo	PERSON
dpc-4503	19	2	biogen	ORG
dpc-4503	19	3	leo pharma	PERSON
dpc-4503	19	4	lilly	ORG
dpc-4503	19	5	janssen	GPE
dpc-4503	19	6	novartis	LOC
dpc-4503	19	7	sanofi genzyme	ORG
dpc-4503	19	8	ucb-pharma	ORG
dpc-4503	20	1	m. valenti	PERSON
dpc-4503	20	2	sanofi	ORG
dpc-4503	20	3	leo pharma	PERSON
dpc-4503	20	4	eli lilly	ORG
dpc-4503	20	5	novartis	LOC
dpc-4503	20	6	janssen	GPE
dpc-4503	20	7	boehringer ingelheim	ORG
dpc-4503	21	1	s. giordano	PERSON
dpc-4503	21	2	f. repetto	PERSON
dpc-4503	21	3	c. a. maronese	PERSON
dpc-4503	21	4	f. martora	PERSON
dpc-4503	21	5	s.r. mercuri	ORG
dpc-4503	22	1	2	CARDINAL
dpc-4503	23	1	2024;14(4):e2024250	CARDINAL
dpc-4503	23	2	approximately 1%	PERCENT
dpc-4503	24	1	1	CARDINAL
dpc-4503	25	1	1	CARDINAL
dpc-4503	27	1	tnf)-alfa	ORG
dpc-4503	27	2	3	CARDINAL
dpc-4503	28	1	anti-tnf	NORP
dpc-4503	28	2	secukinumab	PERSON
dpc-4503	29	1	4	CARDINAL
dpc-4503	29	2	5	CARDINAL
dpc-4503	30	1	secukinumab	PERSON
dpc-4503	30	2	the us food and drug administration	ORG
dpc-4503	30	3	fda	ORG
dpc-4503	30	4	31	CARDINAL
dpc-4503	30	5	2023	CARDINAL
dpc-4503	31	1	1.8	CARDINAL
dpc-4503	31	2	95%	PERCENT
dpc-4503	31	3	ci	PERSON
dpc-4503	31	4	1.5-2.3	CARDINAL
dpc-4503	32	1	6	CARDINAL
dpc-4503	33	1	two	CARDINAL
dpc-4503	33	2	17	CARDINAL
dpc-4503	33	3	6	CARDINAL
dpc-4503	34	1	hs	PERSON
dpc-4503	34	2	hs	PERSON
dpc-4503	34	3	guselkumab	PERSON
dpc-4503	34	4	tildrakizumab	PERSON
dpc-4503	34	5	risankizumab	PERSON
dpc-4503	34	6	secukinumab	PERSON
dpc-4503	34	7	hs	PERSON
dpc-4503	34	8	two	CARDINAL
dpc-4503	34	9	3	CARDINAL
dpc-4503	34	10	5	CARDINAL
dpc-4503	34	11	8	CARDINAL
dpc-4503	35	1	3	CARDINAL
dpc-4503	36	1	9	CARDINAL
dpc-4503	37	1	risankizumab	PERSON
dpc-4503	37	2	guselkumab	PERSON
dpc-4503	37	3	2	CARDINAL
dpc-4503	38	1	10	CARDINAL
dpc-4503	38	2	11	CARDINAL
dpc-4503	40	1	il)-17	ORG
dpc-4503	42	1	hs	PERSON
dpc-4503	43	1	11	CARDINAL
dpc-4503	43	2	italian	NORP
dpc-4503	44	1	each week	DATE
dpc-4503	45	1	41	CARDINAL
dpc-4503	45	2	at least 16 weeks	DATE
dpc-4503	45	3	17	CARDINAL
dpc-4503	45	4	52 weeks	DATE
dpc-4503	46	1	27	CARDINAL
dpc-4503	46	2	5	CARDINAL
dpc-4503	46	3	5	CARDINAL
dpc-4503	47	1	39%	PERCENT
dpc-4503	47	2	74.3%	PERCENT
dpc-4503	47	3	77.8%	PERCENT
dpc-4503	47	4	16	CARDINAL
dpc-4503	47	5	32	DATE
dpc-4503	47	6	52 weeks	DATE
dpc-4503	48	1	aes	ORG
dpc-4503	48	2	aes	ORG
dpc-4503	49	1	ae	ORG
dpc-4503	49	2	four	CARDINAL
dpc-4503	50	1	hs	PERSON
dpc-4503	50	2	hs	PERSON
dpc-4503	51	1	gargiulo l.	PERSON
dpc-4503	51	2	ibba l.	PERSON
dpc-4503	51	3	first	ORDINAL
dpc-4503	52	1	mario valenti	PERSON
dpc-4503	52	2	md	GPE
dpc-4503	52	3	biomedical sciences	ORG
dpc-4503	52	4	humanitas university	ORG
dpc-4503	52	5	pieve emanuele	PERSON
dpc-4503	52	6	italy	GPE
dpc-4503	54	1	2024;14(4):e2024250 3	CARDINAL
dpc-4503	54	2	11	CARDINAL
dpc-4503	54	3	italian	NORP
dpc-4503	54	4	january 2020	DATE
dpc-4503	54	5	december 2023	DATE
dpc-4503	55	1	41	CARDINAL
dpc-4503	55	2	at least 16 weeks	DATE
dpc-4503	56	1	hurley stage	PERSON
dpc-4503	56	2	4	CARDINAL
dpc-4503	56	3	4	CARDINAL
dpc-4503	57	1	italian	NORP
dpc-4503	57	2	12	CARDINAL
dpc-4503	59	1	secukinumab	GPE
dpc-4503	59	2	23	CARDINAL
dpc-4503	59	3	5	CARDINAL
dpc-4503	59	4	13	CARDINAL
dpc-4503	60	1	institutional review board	ORG
dpc-4503	62	1	1964	DATE
dpc-4503	63	1	week 16, week 32, and week 52	DATE
dpc-4503	66	1	at least 50%	PERCENT
dpc-4503	66	2	17	CARDINAL
dpc-4503	67	1	at least 55%	PERCENT
dpc-4503	67	2	ihs4	GPE
dpc-4503	67	3	ihs455	PERSON
dpc-4503	68	1	18	CARDINAL
dpc-4503	69	1	aes	ORG
dpc-4503	69	2	aes	ORG
dpc-4503	69	3	aes	ORG
dpc-4503	71	1	microsoft	ORG
dpc-4503	72	1	41	CARDINAL
dpc-4503	72	2	at least 16 weeks	DATE
dpc-4503	72	3	17	CARDINAL
dpc-4503	72	4	one year	DATE
dpc-4503	74	1	secukinumab	PERSON
dpc-4503	74	2	27	CARDINAL
dpc-4503	74	3	5	CARDINAL
dpc-4503	74	4	guselkumab	PERSON
dpc-4503	74	5	5	CARDINAL
dpc-4503	74	6	2	CARDINAL
dpc-4503	74	7	1	CARDINAL
dpc-4503	74	8	1	CARDINAL
dpc-4503	75	1	twenty-eight	CARDINAL
dpc-4503	75	2	68.3%	PERCENT
dpc-4503	75	3	15	CARDINAL
dpc-4503	76	1	thirteen	CARDINAL
dpc-4503	76	2	31.7%	PERCENT
dpc-4503	76	3	27.94	CARDINAL
dpc-4503	76	4	4.65	CARDINAL
dpc-4503	77	1	twenty-three	CARDINAL
dpc-4503	77	2	56.1%	PERCENT
dpc-4503	77	3	2	CARDINAL
dpc-4503	78	1	slightly more than half	CARDINAL
dpc-4503	78	2	56.1%	PERCENT
dpc-4503	79	1	85.4%	PERCENT
dpc-4503	79	2	adalimumab	PERSON
dpc-4503	80	1	17	CARDINAL
dpc-4503	80	2	41.5%	PERCENT
dpc-4503	80	3	24	CARDINAL
dpc-4503	80	4	58.5%	PERCENT
dpc-4503	80	5	hurley	PERSON
dpc-4503	81	1	1	CARDINAL
dpc-4503	82	1	29.49	CARDINAL
dpc-4503	82	2	21.93	CARDINAL
dpc-4503	82	3	21.39	CARDINAL
dpc-4503	82	4	17.64	CARDINAL
dpc-4503	82	5	16 weeks	DATE
dpc-4503	82	6	15.29	CARDINAL
dpc-4503	82	7	11.65	CARDINAL
dpc-4503	82	8	32 weeks	DATE
dpc-4503	82	9	10.83	CARDINAL
dpc-4503	82	10	9.91	CARDINAL
dpc-4503	82	11	one year	DATE
dpc-4503	82	12	1a	CARDINAL
dpc-4503	83	1	20.88	CARDINAL
dpc-4503	83	2	7.08	CARDINAL
dpc-4503	83	3	1b	CARDINAL
dpc-4503	84	1	weeks 16, 32	DATE
dpc-4503	84	2	52	CARDINAL
dpc-4503	84	3	15.05	CARDINAL
dpc-4503	84	4	6.45	CARDINAL
dpc-4503	84	5	10.8	CARDINAL
dpc-4503	84	6	6.78	CARDINAL
dpc-4503	84	7	7	CARDINAL
dpc-4503	84	8	5.71	CARDINAL
dpc-4503	85	1	39%	PERCENT
dpc-4503	85	2	74.3%	PERCENT
dpc-4503	85	3	77.8%	PERCENT
dpc-4503	85	4	16	CARDINAL
dpc-4503	85	5	32	DATE
dpc-4503	85	6	52 weeks	DATE
dpc-4503	85	7	2a	CARDINAL
dpc-4503	86	1	at least 55%	PERCENT
dpc-4503	86	2	ihs4	GPE
dpc-4503	86	3	14.6%	PERCENT
dpc-4503	86	4	45.7%	PERCENT
dpc-4503	86	5	88.9%	PERCENT
dpc-4503	86	6	weeks 16, 32	DATE
dpc-4503	86	7	52	DATE
dpc-4503	86	8	2b	CARDINAL
dpc-4503	88	1	ten	CARDINAL
dpc-4503	88	2	at least one	CARDINAL
dpc-4503	88	3	24.4%	PERCENT
dpc-4503	89	1	aes	ORG
dpc-4503	89	2	four	CARDINAL
dpc-4503	89	3	three	CARDINAL
dpc-4503	90	1	aes	ORG
dpc-4503	90	2	aes	ORG
dpc-4503	91	1	4	CARDINAL
dpc-4503	92	1	2024;14(4):e2024250	CARDINAL
dpc-4503	92	2	22	CARDINAL
dpc-4503	94	1	esme et al	PERSON
dpc-4503	95	1	23	CARDINAL
dpc-4503	95	2	five	CARDINAL
dpc-4503	95	3	adalimumab	PERSON
dpc-4503	96	1	four	CARDINAL
dpc-4503	96	2	five	CARDINAL
dpc-4503	96	3	hiscr	GPE
dpc-4503	96	4	week 12	DATE
dpc-4503	96	5	23	CARDINAL
dpc-4503	98	1	16 weeks	DATE
dpc-4503	98	2	24	CARDINAL
dpc-4503	100	1	il-17a	PRODUCT
dpc-4503	100	2	17	CARDINAL
dpc-4503	100	3	19	CARDINAL
dpc-4503	101	1	secukinumab	PERSON
dpc-4503	101	2	3	CARDINAL
dpc-4503	101	3	hiscr	GPE
dpc-4503	101	4	week 16	DATE
dpc-4503	101	5	secukinumab every two weeks	DATE
dpc-4503	101	6	every four weeks	DATE
dpc-4503	101	7	8	CARDINAL
dpc-4503	102	1	52 weeks	DATE
dpc-4503	102	2	8	CARDINAL
dpc-4503	103	1	week 28	DATE
dpc-4503	103	2	41%	PERCENT
dpc-4503	103	3	31	CARDINAL
dpc-4503	104	1	20	CARDINAL
dpc-4503	105	1	spanish	NORP
dpc-4503	105	2	48.9%	PERCENT
dpc-4503	105	3	47	CARDINAL
dpc-4503	105	4	21	CARDINAL
dpc-4503	106	1	secukinumab	PERSON
dpc-4503	106	2	first	ORDINAL
dpc-4503	106	3	1	CARDINAL
dpc-4503	107	1	41 n (%	MONEY
dpc-4503	107	2	28	CARDINAL
dpc-4503	107	3	68.3	CARDINAL
dpc-4503	107	4	at least one	CARDINAL
dpc-4503	107	5	23	CARDINAL
dpc-4503	107	6	56.1	CARDINAL
dpc-4503	107	7	23	CARDINAL
dpc-4503	107	8	56.1	CARDINAL
dpc-4503	107	9	35	CARDINAL
dpc-4503	107	10	85.4	CARDINAL
dpc-4503	107	11	17	CARDINAL
dpc-4503	107	12	41.5	CARDINAL
dpc-4503	107	13	hurley iii 24	PERSON
dpc-4503	107	14	58.5	CARDINAL
dpc-4503	107	15	13	CARDINAL
dpc-4503	107	16	31.7	CARDINAL
dpc-4503	107	17	secukinumab 27	DATE
dpc-4503	107	18	65.9	CARDINAL
dpc-4503	107	19	5	CARDINAL
dpc-4503	107	20	12.2	CARDINAL
dpc-4503	107	21	2	CARDINAL
dpc-4503	107	22	4.9	CARDINAL
dpc-4503	107	23	1	CARDINAL
dpc-4503	107	24	2.4	CARDINAL
dpc-4503	107	25	5	CARDINAL
dpc-4503	107	26	12.2	CARDINAL
dpc-4503	107	27	age, years 40.59	DATE
dpc-4503	107	28	15	CARDINAL
dpc-4503	107	29	27.94	CARDINAL
dpc-4503	107	30	4.65	CARDINAL
dpc-4503	107	31	29.49	CARDINAL
dpc-4503	107	32	21.93	CARDINAL
dpc-4503	107	33	20.88	CARDINAL
dpc-4503	107	34	7.08	CARDINAL
dpc-4503	107	35	4	CARDINAL
dpc-4503	108	1	1	CARDINAL
dpc-4503	108	2	52 weeks	DATE
dpc-4503	109	1	4	CARDINAL
dpc-4503	111	1	2024;14(4):e2024250 5	CARDINAL
dpc-4503	111	2	1	CARDINAL
dpc-4503	111	3	2	CARDINAL
dpc-4503	111	4	3	CARDINAL
dpc-4503	111	5	9	CARDINAL
dpc-4503	112	1	2	CARDINAL
dpc-4503	112	2	week 12	DATE
dpc-4503	112	3	27	CARDINAL
dpc-4503	113	1	9	CARDINAL
dpc-4503	113	2	27	CARDINAL
dpc-4503	115	1	tildrakizumab	PERSON
dpc-4503	116	1	28	CARDINAL
dpc-4503	116	2	nine	CARDINAL
dpc-4503	116	3	15 months	DATE
dpc-4503	117	1	15 months	DATE
dpc-4503	117	2	aes	ORG
dpc-4503	117	3	28	CARDINAL
dpc-4503	118	1	seven	CARDINAL
dpc-4503	118	2	adalimumab	PERSON
dpc-4503	118	3	24 weeks	DATE
dpc-4503	118	4	29	CARDINAL
dpc-4503	119	1	risankizumab	PERSON
dpc-4503	119	2	2	CARDINAL
dpc-4503	120	1	10	CARDINAL
dpc-4503	121	1	six	CARDINAL
dpc-4503	121	2	six months	DATE
dpc-4503	121	3	30	CARDINAL
dpc-4503	122	1	guselkumab	PERSON
dpc-4503	122	2	2	CARDINAL
dpc-4503	122	3	31,32	CARDINAL
dpc-4503	123	1	one	CARDINAL
dpc-4503	123	2	32	CARDINAL
dpc-4503	124	1	ihs4	GPE
dpc-4503	124	2	48 weeks	DATE
dpc-4503	124	3	more than half	CARDINAL
dpc-4503	124	4	hiscr	GPE
dpc-4503	124	5	week 16	DATE
dpc-4503	125	1	4	CARDINAL
dpc-4503	125	2	33	DATE
dpc-4503	125	3	34	CARDINAL
dpc-4503	126	1	41	CARDINAL
dpc-4503	128	1	first	ORDINAL
dpc-4503	131	1	hs	PERSON
dpc-4503	132	1	il-17ra	ORG
dpc-4503	133	1	25	CARDINAL
dpc-4503	134	1	il-17a	PRODUCT
dpc-4503	134	2	10	CARDINAL
dpc-4503	134	3	26	CARDINAL
dpc-4503	135	1	26	CARDINAL
dpc-4503	136	1	every two weeks	DATE
dpc-4503	136	2	2	CARDINAL
dpc-4503	137	1	4	CARDINAL
dpc-4503	138	1	6	CARDINAL
dpc-4503	139	1	2024;14(4):e2024250 13	DATE
dpc-4503	140	1	european medicines	ORG
dpc-4503	141	1	tremfya	PERSON
dpc-4503	141	2	guselkumab	PERSON
dpc-4503	142	1	2017	CARDINAL
dpc-4503	143	1	2023	CARDINAL
dpc-4503	143	2	december 28	DATE
dpc-4503	144	1	14	DATE
dpc-4503	145	1	european medicines	ORG
dpc-4503	146	1	skyrizi	PERSON
dpc-4503	146	2	risankizumab	ORG
dpc-4503	147	1	2019	DATE
dpc-4503	148	1	2023	CARDINAL
dpc-4503	148	2	december 28	DATE
dpc-4503	149	1	https://www.ema.europa.eu/en/medicines/human/epar/skyrizi 15	DATE
dpc-4503	150	1	european medicines	ORG
dpc-4503	151	1	kyntheum	PERSON
dpc-4503	151	2	brodalumab	PERSON
dpc-4503	151	3	2017	CARDINAL
dpc-4503	152	1	2023	CARDINAL
dpc-4503	152	2	december 28	DATE
dpc-4503	153	1	16	DATE
dpc-4503	154	1	european medicines	ORG
dpc-4503	155	1	bimzelx	PERSON
dpc-4503	156	1	2021	CARDINAL
dpc-4503	157	1	2023	CARDINAL
dpc-4503	157	2	december 28	DATE
dpc-4503	158	1	https://www.ema.europa.eu/en/medicines/human/epar/ bimzelx 17	ORG
dpc-4503	159	1	kimball ab	PERSON
dpc-4503	159	2	sobell jm	PERSON
dpc-4503	159	3	zouboulis cc	PERSON
dpc-4503	160	1	hiscr	PERSON
dpc-4503	160	2	2	CARDINAL
dpc-4503	162	1	989	CARDINAL
dpc-4503	163	1	doi:10.1111	ORG
dpc-4503	163	2	18	CARDINAL
dpc-4503	163	3	van straalen kr	PERSON
dpc-4503	163	4	ihs4-55	ORG
dpc-4503	165	1	2023;37(2):395-401	CARDINAL
dpc-4503	166	1	doi:10.1111	ORG
dpc-4503	168	1	2023;15(10):2450	CARDINAL
dpc-4503	168	2	2023	CARDINAL
dpc-4503	168	3	oct 11	DATE
dpc-4503	169	1	20	CARDINAL
dpc-4503	170	1	italian	NORP
dpc-4503	172	1	2021;35(7):e441-e442	ORG
dpc-4503	173	1	doi:10.1111	ORG
dpc-4503	173	2	21	CARDINAL
dpc-4503	177	1	2023	CARDINAL
dpc-4503	178	1	10.1007	CARDINAL
dpc-4503	179	1	european medicines	ORG
dpc-4503	180	1	cosentyx	PERSON
dpc-4503	180	2	secukinumab	PERSON
dpc-4503	181	1	2014	DATE
dpc-4503	182	1	2023	CARDINAL
dpc-4503	182	2	december 28	DATE
dpc-4503	183	1	23	CARDINAL
dpc-4503	184	1	esme p	ORG
dpc-4503	184	2	caliskan e.	PERSON
dpc-4503	185	1	antiinterleukin17a	FAC
dpc-4503	186	1	2022;8(4):342-345	CARDINAL
dpc-4503	187	1	24	CARDINAL
dpc-4503	188	1	kearney n	PERSON
dpc-4503	188	2	hughes	ORG
dpc-4503	188	3	kirby b.	PERSON
dpc-4503	189	1	clin	PERSON
dpc-4503	190	1	2023;48(7):790-792	CARDINAL
dpc-4503	191	1	25	CARDINAL
dpc-4503	192	1	navrazhina k	PERSON
dpc-4503	195	1	2022	CARDINAL
dpc-4503	195	2	233	CARDINAL
dpc-4503	196	1	10.1111	CARDINAL
dpc-4503	197	1	26	CARDINAL
dpc-4503	197	2	frew jw	PERSON
dpc-4503	197	3	navrazhina k	PERSON
dpc-4503	197	4	krueger jg	PERSON
dpc-4503	200	1	2021	CARDINAL
dpc-4503	200	2	27	CARDINAL
dpc-4503	201	1	jemec gbe	PERSON
dpc-4503	201	2	2	CARDINAL
dpc-4503	202	1	1	CARDINAL
dpc-4503	203	1	bukvić mokos z	PERSON
dpc-4503	203	2	marinović b.	PERSON
dpc-4503	203	3	clin	PERSON
dpc-4503	204	1	2023;41(5	CARDINAL
dpc-4503	204	2	564-575	CARDINAL
dpc-4503	205	1	doi:10.1016/j.clindermatol.2023.08.020 2	FAC
dpc-4503	206	1	three	CARDINAL
dpc-4503	208	1	2013;133(6	CARDINAL
dpc-4503	208	2	1506-1511	DATE
dpc-4503	209	1	doi:10.1038	ORG
dpc-4503	209	2	3	CARDINAL
dpc-4503	209	3	navrazhina k	PERSON
dpc-4503	210	1	j am	PERSON
dpc-4503	211	1	december 3	DATE
dpc-4503	211	2	2023	DATE
dpc-4503	212	1	4	CARDINAL
dpc-4503	213	1	maronese	NORP
dpc-4503	213	2	genovese g	PERSON
dpc-4503	214	1	marzano av	PERSON
dpc-4503	215	1	rev clin immunol	PERSON
dpc-4503	216	1	december 22	DATE
dpc-4503	216	2	2023	CARDINAL
dpc-4503	217	1	5	CARDINAL
dpc-4503	217	2	european medicines	ORG
dpc-4503	218	1	cosentyx	PERSON
dpc-4503	218	2	secukinumab	PERSON
dpc-4503	219	1	2015	DATE
dpc-4503	220	1	2023	CARDINAL
dpc-4503	220	2	december 28	DATE
dpc-4503	222	1	kridin k	PERSON
dpc-4503	222	2	shani m	PERSON
dpc-4503	224	1	j am	PERSON
dpc-4503	225	1	2023;88(5):e231	CARDINAL
dpc-4503	225	2	doi:10.1016/j.jaad.2018.11.036 7	GPE
dpc-4503	225	3	macca l	PERSON
dpc-4503	225	4	li	PERSON
dpc-4503	227	1	2023;10:1208817	CARDINAL
dpc-4503	227	2	2023	CARDINAL
dpc-4503	227	3	jul 7	DATE
dpc-4503	228	1	kimball ab	PERSON
dpc-4503	228	2	jemec gbe	PERSON
dpc-4503	228	3	secukinumab	PERSON
dpc-4503	228	4	week 16 and week 52	DATE
dpc-4503	228	5	two	CARDINAL
dpc-4503	228	6	3	CARDINAL
dpc-4503	229	1	lancet	ORG
dpc-4503	230	1	2023;401(10378):747	CARDINAL
dpc-4503	231	1	doi:10.1016	PERSON
dpc-4503	232	1	kimball ab	PERSON
dpc-4503	232	2	jemec gbe	PERSON
dpc-4503	232	3	sayed cj	PERSON
dpc-4503	233	1	two	CARDINAL
dpc-4503	233	2	48-week	DATE
dpc-4503	233	3	3	CARDINAL
dpc-4503	234	1	lancet	ORG
dpc-4503	235	1	2024;403(10443):2504-2519	DATE
dpc-4503	236	1	doi:10.1016	GPE
dpc-4503	238	1	kimball ab	PERSON
dpc-4503	238	2	prens ep	PERSON
dpc-4503	238	3	2	CARDINAL
dpc-4503	240	1	2023;13(5):1099-1111	DATE
dpc-4503	241	1	023	CARDINAL
dpc-4503	242	1	kimball ab	PERSON
dpc-4503	242	2	guselkumab	PERSON
dpc-4503	242	3	2	CARDINAL
dpc-4503	244	1	2023;37(10):2098-2108	CARDINAL
dpc-4503	245	1	doi:10.1111/jdv.19252 12	ORG
dpc-4503	246	1	gisondi p	PERSON
dpc-4503	246	2	fargnoli mc	PERSON
dpc-4503	247	1	italian	NORP
dpc-4503	249	1	2022;157	DATE
dpc-4503	249	2	1	CARDINAL
dpc-4503	250	1	1):1-78	CARDINAL
dpc-4503	252	1	2024;14(4):e2024250	CARDINAL
dpc-4503	252	2	7	CARDINAL
dpc-4503	252	3	2	CARDINAL
dpc-4503	254	1	2023;37(10):2098-2108	CARDINAL
dpc-4503	256	1	dudink k	PERSON
dpc-4503	256	2	bouwman k	PERSON
dpc-4503	256	3	chen y	PERSON
dpc-4503	256	4	guselkumab	PERSON
dpc-4503	258	1	2023;188(5):601-609	CARDINAL
dpc-4503	259	1	33	CARDINAL
dpc-4503	260	1	rivera-díaz	PERSON
dpc-4503	260	2	pozo t	ORG
dpc-4503	261	1	spanish	NORP
dpc-4503	262	1	efectividad de guselkumab en pacientes	PERSON
dpc-4503	262	2	de práctica clínica	ORG
dpc-4503	263	1	2023;114(9):t755-t762	QUANTITY
dpc-4503	263	2	doi:10.1016/j.ad.2023.06.018 34	ORG
dpc-4503	264	1	martora f	PERSON
dpc-4503	264	2	battista	ORG
dpc-4503	264	3	guselkumab	PERSON
dpc-4503	264	4	risankizumab	PERSON
dpc-4503	265	1	clin	PERSON
dpc-4503	266	1	2023;16:2525-2536	CARDINAL
dpc-4503	267	1	2023	CARDINAL
dpc-4503	267	2	sep 18	DATE
dpc-4503	267	3	doi:10.2147/ccid.s418748	ORG
dpc-4503	267	4	jama dermatol.2021;157(11):1279–1288	GPE
dpc-4503	267	5	doi:10.1001	GPE
dpc-4503	269	1	28	DATE
dpc-4503	270	1	kok y	PERSON
dpc-4503	270	2	nicolopoulos j	PERSON
dpc-4503	270	3	c. tildrakizumab	PERSON
dpc-4503	270	4	15 months	DATE
dpc-4503	270	5	australian	NORP
dpc-4503	271	1	australas j	PERSON
dpc-4503	272	1	2021;62(2):e313	CARDINAL
dpc-4503	273	1	doi:10.1111	ORG
dpc-4503	274	1	koszegi b	PERSON
dpc-4503	274	2	wilson	PERSON
dpc-4503	274	3	cowan tl	PERSON
dpc-4503	274	4	murrell df	ORG
dpc-4503	274	5	tildrakizumab	PERSON
dpc-4503	274	6	adalimumab	PERSON
dpc-4503	274	7	30-month	DATE
dpc-4503	275	1	clin	PERSON
dpc-4503	276	1	2023;48(11):1266-1269	CARDINAL
dpc-4503	277	1	30	CARDINAL
dpc-4503	278	1	repetto f	PERSON
dpc-4503	278	2	burzi l	ORG
dpc-4503	280	1	2022	CARDINAL
dpc-4503	280	2	sep 28	DATE
dpc-4503	281	1	31	CARDINAL
dpc-4503	282	1	kimball ab	PERSON
dpc-4503	282	2	guselkumab	PERSON